55,435 Shares in Organon & Co. (NYSE:OGN) Purchased by Range Financial Group LLC

Range Financial Group LLC bought a new stake in shares of Organon & Co. (NYSE:OGN) in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund bought 55,435 shares of the company’s stock, valued at approximately $827,000.

Other large investors have also recently made changes to their positions in the company. Barclays PLC grew its holdings in Organon & Co. by 238.0% in the third quarter. Barclays PLC now owns 119,483 shares of the company’s stock valued at $2,285,000 after purchasing an additional 84,136 shares during the period. Public Sector Pension Investment Board increased its holdings in Organon & Co. by 8.0% in the 2nd quarter. Public Sector Pension Investment Board now owns 565,866 shares of the company’s stock worth $11,713,000 after acquiring an additional 41,954 shares in the last quarter. Weiss Asset Management LP acquired a new position in Organon & Co. during the third quarter worth $32,966,000. Cerity Partners LLC raised its position in Organon & Co. by 94.0% during the third quarter. Cerity Partners LLC now owns 667,340 shares of the company’s stock worth $12,766,000 after acquiring an additional 323,308 shares during the period. Finally, Beddow Capital Management Inc. lifted its holdings in Organon & Co. by 38.8% during the third quarter. Beddow Capital Management Inc. now owns 306,675 shares of the company’s stock valued at $5,867,000 after purchasing an additional 85,775 shares in the last quarter. 77.43% of the stock is currently owned by institutional investors and hedge funds.

Organon & Co. Trading Up 1.7 %

Organon & Co. stock traded up $0.26 during midday trading on Tuesday, hitting $15.74. 2,641,994 shares of the stock were exchanged, compared to its average volume of 2,840,377. The stock’s 50-day simple moving average is $15.54 and its 200 day simple moving average is $18.51. Organon & Co. has a fifty-two week low of $13.87 and a fifty-two week high of $23.10. The company has a current ratio of 1.70, a quick ratio of 1.21 and a debt-to-equity ratio of 17.73. The stock has a market capitalization of $4.05 billion, a price-to-earnings ratio of 3.12, a PEG ratio of 0.81 and a beta of 0.76.

Organon & Co. (NYSE:OGN) last released its quarterly earnings results on Thursday, October 31st. The company reported $0.87 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.90 by ($0.03). The company had revenue of $1.58 billion during the quarter, compared to analysts’ expectations of $1.56 billion. Organon & Co. had a net margin of 20.30% and a return on equity of 644.70%. Organon & Co.’s revenue was up 4.1% on a year-over-year basis. During the same period last year, the firm posted $0.78 earnings per share. On average, equities analysts anticipate that Organon & Co. will post 3.89 EPS for the current year.

Organon & Co. Dividend Announcement

The firm also recently declared a quarterly dividend, which was paid on Thursday, December 12th. Shareholders of record on Tuesday, November 12th were paid a dividend of $0.28 per share. The ex-dividend date of this dividend was Tuesday, November 12th. This represents a $1.12 dividend on an annualized basis and a yield of 7.12%. Organon & Co.’s dividend payout ratio (DPR) is presently 22.22%.

Wall Street Analyst Weigh In

Separately, Evercore ISI upgraded Organon & Co. to a “strong-buy” rating in a research report on Wednesday, September 18th.

Organon & Co. Company Profile

Organon & Co develops and delivers health solutions through a portfolio of prescription therapies and medical devices within women's health in the United States and internationally. Its women's health portfolio comprises contraception and fertility brands, such as Nexplanon, a long-acting reversible contraceptive; NuvaRing, a monthly vaginal contraceptive ring; Cerazette, a daily pill used to prevent pregnancy; Marvelon, progestin and estrogen used as daily pills to prevent pregnancy; Follistim AQ, used to promote the development of multiple ovarian follicles in assisted reproduction technology procedures; Elonva, an ovarian follicle stimulant; Ganirelix Acetate Injection, an injectable antagonist; and Jada, for abnormal postpartum uterine bleeding or hemorrhage.